GW Pharmaceuticals SWOT Analysis, USP & Competitors

GW Pharmaceuticals

Parent Company

GW Pharmaceuticals

Category

Biopharmaceutical

Sector

Pharma and Healthcare

Tagline/ Slogan

-

USP

Its MS treatment product

GW Pharmaceuticals STP

Segment

Healthcare

Target Group

People suffering from multiple sclerosis, epilepsy and cancer

Positioning

Focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform

GW Pharmaceuticals SWOT Analysis

Strengths

1. GW Pharmaceuticals has the only cultivation license in the United Kingdom from the Home Office and theMHRA, to cultivate cannabis from seeds and clones to conduct scientific research concerning the medicinal uses of the plant
2. GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in North America
3. GW is researching a large number of cannabinoids, each of which has different effects and applications

4.Collaboration with various educational institutes for R&D.

5. Strong expertise in the industry

Weaknesses

1. Health issues due to side effects of cannabis
2.Human rights issues as cannabis is considered as a harmful drug
3.Legal issues in cultivating medical cannabis

4.Requires very high quality control in cultivating medical cannabis

Opportunities

1. Its cannabis-based product, Epidiolex, developed for experimental treatment of epilepsy, will undergo stage-two trials in the US in 2014
2. Tie ups with large hospitals can be a huge opportunity
3.Scope of entering into other segments of pharmaceuticals

Threats

1.It has only one major drug Sativex, contribute maximum to the revenue
2.Need for continuous innovation
3.Stringent government rules and quality control measures

GW Pharmaceuticals Competition

Competitors

1.Shire UK
2.Teva UK Limited
3.Meda Pharmaceuticals UK